Gilead announced a couple of weeks ago that it would be advancing the treatment – also known as selonsertib – through to phase III trials following ‘encouraging’ phase II results.
As part of that recent study, selonsertib was tested both on its own and in combination with its investigational monoclonal antibody simtuzumab.
The latter did not have as big an impact as had been hoped and will not be taken forward into the upcoming phase III trials.
In its third quarter earnings report released yesterday (1 November), Gilead added that another compound, GS-5745, would not be progressed any further for the treatment of Crohn’s Disease.
Abzena shares closed at 39.62p on Tuesday.
Story by ProactiveInvestors